Topotecan |
Katalog-Nr.GC17833 |
Topotecan (SKF 104864A; NSC 609669) ist ein oral wirksamer und potenter Topoisomerase-I-Hemmer. Topotecan induziert einen Zellzyklusarrest in der G0/G1- und S-Phase und fÖrdert die Apoptose. Topotecan zeigt AntikrebsaktivitÄt.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123948-87-8
Sample solution is provided at 25 µL, 10mM.
Topotecan (SKF104864) is an inhibitor of topoisomerase 1 and semisynthetic analogue of camptothecin [1].
Topotecan (SKF104864) has been reported to have a potent antitumor activity against tumors in murine models. In addition, Topotecan has also shown the potent effect against intravenously implanted P388 leukemia and both intravenously and subcutaneously implanted Lewis lung carcinoma. Topotecan has noted the activity against subcutaneously implanted solid tumors including chemorefractory tumors and human colon carcinoma xenograft HT-29. Topotecan has been found to induce regressions in the lung tumor model (Lewis lung carcinoma and B16 melanoma), compared to camptothecin and 9-amino-camptothecin. In the preclinical toxicology studies, Topotecan has been revealed to have a concentration-dependent, reversible and limited toxoicity to rapidly proliferation tissues such as bone marrow and gastro-intestinal epithelium [1].
References:
[1] Creemers GJ1, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irenotecan. Cancer Treat Rev. 1994 Jan;20(1):73-96.
Average Rating: 5
(Based on Reviews and 32 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *